Arbutus Biopharma Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arbutus Biopharma Corporation
Any delays caused by unpredictable regulatory reviews related to the export of genetic materials threaten to derail the inclusion of China in international clinical trials, caution two trade groups representing the pharma industry in the country.
Cognoa’s Sharief Taraman tells Medtech Insight that artificial intelligence and machine learning can help bring new pediatric diagnostics and treatments to market but it’s important to avoid perpetuating racial, gender and other disparities.
The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.
In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Genevant Sciences
- Inex Pharmaceuticals Corporation
- OnCore Biopharma, Inc, (Enantigen Therapeutics, Inc.)
- Tekmira Pharmaceuticals Corporation (TKMR)
- Protiva Biotherapeutics Inc.